New pyrazolopyridine and pyrazolothiazole-based compounds as anti-proliferative agents targeting c-Met kinase inhibition: design, synthesis, biological evaluation, and computational studies
作者:Zahra M. Alamshany、Eman M. Algamdi、Ismail M. M. Othman、Manal M. Anwar、Eman S. Nossier
DOI:10.1039/d3ra01931d
日期:——
human cancer treatment. This work deals with the design and synthesis of a new set of derivatives bearing pyrazolo[3,4-b]pyridine, pyrazolo[3,4-b]thieno[3,2-e]pyridine, and pyrazolo[3,4-d]thiazole-5-thione scaffolds, 5a,b, 8a–f, and 10a,b, respectively, utilizing 3-methyl-1-tosyl-1H-pyrazol-5(4H)-one (1) as a key starting material. All the new compounds were evaluated as antiproliferative agents against
c-Met 酪氨酸激酶在致癌过程中起关键作用。抑制 c-Met 已成为人类癌症治疗的一个有吸引力的目标。这项工作涉及设计和合成一组新的衍生物,包括吡唑并[3,4- b ]吡啶、吡唑并[3,4- b ]噻吩并[3,2-e]吡啶和吡唑[3,4- d ]thiazole-5-thione 支架,5a,b、8a–f和10a,b,分别利用 3-methyl-1-tosyl-1 H -pyrazol-5(4 H )-one ( 1) 作为关键起始材料。使用 5-氟尿嘧啶和厄洛替尼作为两种标准药物,所有新化合物均被评估为抗 HepG-2、MCF-7 和 HCT-116 人类癌细胞系的抗增殖剂。化合物5a、b和10a、b代表最有前途的细胞毒活性,IC 50值范围为 3.42 ± 1.31 至 17.16 ± 0.37 μM。5a和5b均显示出对 HepG-2 的最大细胞毒性和选择性,IC 50值分别为 3